US · Healthcare · Medical Devices
EPS came in at -0.52 against a street estimate of -0.53 — a beat of 1.9%.
Analysts rate Beta Bionics, Inc. Common Stock a buy (11 buy, 4 hold, 0 sell out of 15) with an average price target of $25.10.
MIXED Record Q3 sales and raised revenue floor support growth, but 3D Intelligence faces a resubmission delay and Mint will dilute 2027 margins. Q3 FY26 Analysts focused on 3D’s FDA delay, Mint’s ramp and coverage, manufacturing capacity, margins, and future algorithms. Management emphasized validation—not algorithm performance—as the 3D issue. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| Eventide Asset Management, LLC | 11.59% |
| Soleus Capital Management, L.P. | 8.14% |
| Morgan Stanley - Brokerage Accounts | 7.91% |
| Sands Capital Ventures, LLC | 6.87% |
| BlackRock Inc | 6.19% |
| Point72 Asset Management, L.P. | 4.18% |
| Vanguard Capital Management, LLC | 3.30% |
| Vestal Point Capital LP | 2.97% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $35,505, up from $27,253 in the same quarter of 2025. • Nine-month 2026 net sales were $95,144 | 2026-10-27 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $35.5 million, up 30% from $27.3 million in the third quarter of 2025. • Gross margin increased | 2026-10-27 |
| Company announcement · Q3 2026 BETA BIONICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company conducting public offering of 7,652,175 shares at $17.25 per share • Additional 1,043,48 | 2026-09-17 |
| Reg FD disclosure · Q3 2026 BETA BIONICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • FDA cleared Mint patch pump on September 14, 2026 • iLet real-world data: 84% of users met Ameri | 2026-09-15 |
| Quarterly report · Q2 2026 BETA BIONICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net sales for Q2 2026: $32.0 million (up 38% from $23.2 million in Q2 2025) • Net sal | 2026-07-29 |
| Results announced · Q3 2026 BETA BIONICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net sales: $32.0 million in Q2 2026, up 38% from $23.2 million in Q2 2025 • Six-mo | 2026-07-29 |
| Shareholder vote results · Q2 2026 BETA BIONICS, INC. (BBNX) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company held 2026 Annual Meeting of Stockholders on May 21, 2026 • 44,561,695 total | 2026-05-22 |
| Reg FD disclosure · Q2 2026 BETA BIONICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Beta Bionics, Inc. (ticker: BBNX, Nasdaq) • Report date: May 21, 2026 • Headquarte | 2026-05-21 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Beta Bionics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.